Meta-Analysis of the Pharmacogenetics of ARMS2 A69S Polymorphism and the Response to Advanced Age-Related Macular Degeneration
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) causes irreversible vision loss, and targeted anti-vascular endothelial growth factor (VEGF) therapy is now the most common and effective treatment. The aim of this meta-analysis is to discuss whether genetic polymorphism of ARMS2 A69S could confer susceptibility to advanced AMD with the response to anti-VEGF treatment. We performed a meta-analysis of relevant published studies selected through electronic databases. A total of 21 preferred studies regarding the association between ARMS2 gene and anti-VEGF treatment response in advanced AMD were generally included in the meta-analysis. The pooled results demonstrated that the carriage of G allele for ARMS2 A69S presented a better clinical prognosis for advanced AMD treated with anti-VEGF drugs (OR = 1.38, 95% CI = 1.13–1.69, p = 0.002). In addition, in the subgroup analysis based on ethnicity, ARMS2 polymorphisms were more likely to be a positive responder for East Asian patients (OR = 1.67, 95% CI = 1.29–2.16, p < 0.001). This meta-analysis through a series of rigorous methodology data demonstrated a significant association between ARMS2 A69S polymorphism and the anti-VEGF treatment response in advanced AMD, especially among East Asian population. Numerous well-designed, randomized, multicenter clinical trials with large sample size are required to validate the association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A degree of variability is likely due to the fact that results have emerged from various study types (observational and clinical), with heterogeneous patient populations treated with different anti-VEGF agents, with different dose regimens, and with response to treatment defined using different functional and anatomic end points.6,10,17”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [17]
In the citing paper
“The largest body of evidence on genetic variants associated with treatment response is related to ARMS2/HTRA1, CFH, and VEGFA,6,10,17–19 but even here results are conflicting.”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [17]
In the citing paper
“For example, meta-analyses have reported an association between anti-VEGF treatment response in nAMD and the A69S polymorphism (rs10490924) in the ARMS2 gene,20 the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the CFH gene,21,22 and the rs833061 polymorphism in the VEGFA gene.23”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [20]
Citations
Cites
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
Mechanisms of Age-Related Macular Degeneration
Ambati, J., & Fowler, B. J. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.018 · Cited by 1,021 · cited 1×
“Background Age-related macular degeneration (AMD) is a chronic, progressive condition presenting untreatable in up to 90% of patients, and is a major cause of irreversible blindness in the elderly individuals [1].”
BackgroundHTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Kanda, A., Chen, W., Othman, M., Branham, K. E. H., Brooks, M., Khanna, R., He, S., Lyons, R., Abecasis, G. R., & Swaroop, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703933104 · Cited by 441
The Prevalence of Age-Related Macular Degeneration in Asians
Kawasaki, R., Yasuda, M., Song, S. J., Chen, S.-J., Jonas, J. B., Wang, J. J., Mitchell, P., & Wong, T. Y. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.10.007 · Cited by 438
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA
Fritsche, L. G., Loenhardt, T., Janssen, A., Fisher, S. A., Rivera, A., Keilhauer, C. N., & Weber, B. H. F. (2008) · Nature Genetics · doi:10.1038/ng.170 · Cited by 400
Tong, J.-P., Chan, W.-M., Liu, D. T. L., Lai, T. Y. Y., Choy, K.-W., Pang, C.-P., & Lam, D. S. C. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.012 · Cited by 385
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Bloch, S. B., Larsen, M., & Munch, I. C. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.10.016 · Cited by 377
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W.-K., Ogura, Y., Yeo, I., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 346 · cited 1×
“Although the etiology of AMD is multifactorial, some common risk factors including ageing, smoking, gender, hypertension, obesity and lifetime light exposure have certain epidemiologic associations with its progression [5].”
BackgroundBrantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201
Ranibizumab for Neovascular Age-Related Macular Degeneration
Liew, G., & Mitchell, P. (2007) · New England Journal of Medicine · doi:10.1056/nejmc063011 · Cited by 157
Hagstrom, S. A., Ying, G.-S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., Kim, I. K., Klein, M. L., Maguire, M. G., & Martin, D. F. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.037 · Cited by 142
Kortvely, E., Hauck, S. M., Duetsch, G., Gloeckner, C. J., Kremmer, E., Alge-Priglinger, C. S., Deeg, C. A., & Ueffing, M. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3850 · Cited by 135
Kuroda, Y., Yamashiro, K., Miyake, M., Yoshikawa, M., Nakanishi, H., Oishi, A., Tamura, H., Ooto, S., Tsujikawa, A., & Yoshimura, N. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.053 · Cited by 124 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundIncidence of exudative age-related macular degeneration among elderly americans
Javitt, J. C., Zhou, Z., Maguire, M. G., Fine, S. L., & Willke, R. J. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00495-0 · Cited by 106
Yamashiro, K., Tomita, K., Tsujikawa, A., Nakata, I., Akagi-Kurashige, Y., Miyake, M., Ooto, S., Tamura, H., & Yoshimura, N. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.01.010 · Cited by 93 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundAbedi, F., Wickremasinghe, S., Richardson, A. J., Islam, A. F. M., Guymer, R. H., & Baird, P. N. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.014 · Cited by 82
Sobrin, L., Reynolds, R., Yu, Y., Fagerness, J., Leveziel, N., Bernstein, P. S., Souied, E. H., Daly, M. J., & Seddon, J. M. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.08.015 · Cited by 78 · cited 1×
“[41] suggested that genetic mutation at this locus has conferred a differential risk for choroidal neovascularization versus geographic atrophy.”
BackgroundLotery, A. J., Gibson, J., Cree, A. J., Downes, S. M., Harding, S. P., Rogers, C. A., Reeves, B. C., Ennis, S., & Chakravarthy, U. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.046 · Cited by 64
Andreoli, M. T., Morrison, M. A., Kim, B. J., Chen, L., Adams, S. M., Miller, J. W., DeAngelis, M. M., & Kim, I. K. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.07.002 · Cited by 62
Orlin, A., Hadley, D., Chang, W., Ho, A. C., Brown, G., Kaiser, R. S., Regillo, C. D., Godshalk, A. N., Lier, A., Kaderli, B., et al. (2012) · Retina · doi:10.1097/iae.0b013e31822a2c7c · Cited by 60 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundFauser, S., & Lambrou, G. N. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.11.002 · Cited by 41 · cited 1×
“A large community of AMD patients receiving anti-VEGF treatment could not have their lost vision properly improved or recovered, even with persistent macular edema, despite continuous injection of bevacizumab or ranibizumab [11, 12].”
BackgroundPredicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration
van Asten, F., Rovers, M. M., Lechanteur, Y. T. E., Smailhodzic, D., Muether, P. S., Chen, J., den Hollander, A. I., Fauser, S., Hoyng, C. B., van der Wilt, G. J., et al. (2014) · Ophthalmic Epidemiology · doi:10.3109/09286586.2014.949010 · Cited by 37
Park, U. C., Shin, J. Y., Kim, S. J., Shin, E. S., Lee, J. E., McCarthy, L. C., Newcombe, P. J., Xu, C.-F., Chung, H., & Yu, H. G. (2014) · Retina · doi:10.1097/iae.0b013e3182979e1e · Cited by 35 · cited 2×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundYamashiro, K., Mori, K., Honda, S., Kano, M., Yanagi, Y., Obana, A., Sakurada, Y., Sato, T., Nagai, Y., Hikichi, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09632-0 · Cited by 35 · cited 2×
“[36] argued that ARMS2 A69S was not significantly associated with the changes in visual acuity or anatomic outcomes during the one-year anti-VEGF treatment in treatment-naïve advanced AMD patients, while Kitchens et al.”
BackgroundWood, Kitchens, Kassem, Wood, Stone, Isernhagen, Hancock, Radovich, Waymire, Li, et al. (2013) · Clinical Ophthalmology · doi:10.2147/opth.s39635 · Cited by 34 · cited 2×
“[24] confirmed that A69S was positively correlated with the achievement of dry maculae after three monthly injections of ranibizumab or bevacizumab, suggesting better response of ARMS2 A69S with advanced AMD.”
BackgroundHata, M., Tsujikawa, A., Miyake, M., Yamashiro, K., Ooto, S., Oishi, A., Nakanishi, H., Takahashi, A., & Yoshimura, N. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2688-1 · Cited by 33
Kikushima, W., Sakurada, Y., Yoneyama, S., Sugiyama, A., Tanabe, N., Kume, A., Mabuchi, F., & Iijima, H. (2017) · Scientific Reports · doi:10.1038/srep44020 · Cited by 29 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundPark, D. H., & Kim, I. T. (2011) · Retina · doi:10.1097/iae.0b013e318225290f · Cited by 27
Hu, Z., Xie, P., Ding, Y., Yuan, D., & Liu, Q. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305488 · Cited by 26
Zhou, Y., Chen, C., Wang, Y.-X., Tong, Y., Fang, X., Li, L., & Wang, Z. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0487-2 · Cited by 23
Mohamad, N. A., Ramachandran, V., Isa, H. M., Chan, Y. M., Ngah, N. F., Ching, S. M., Hoo, F. K., Sulaiman, W. A. W., Mat, L. N. I., & Mohamed, M. H. (2019) · Human Genomics · doi:10.1186/s40246-019-0197-3 · Cited by 22
Fang, K., Tian, J., Qing, X., Li, S., Hou, J., Li, J., Yu, W., Chen, D., Hu, Y., & Li, X. (2013) · Journal of Ophthalmology · doi:10.1155/2013/676049 · Cited by 21 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundMatsumiya, W., Honda, S., Yanagisawa, S., Miki, A., Nagai, T., & Tsukahara, Y. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.51 · Cited by 19 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundA novel ARMS2 splice variant is identified in human retina
Wang, G., Scott, W. K., Whitehead, P. G., Court, B. L., Kovach, J. L., Schwartz, S. G., Agarwal, A., Dubovy, S. R., Haines, J. L., & Pericak‐Vance, M. A. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.11.005 · Cited by 16 · cited 1×
“Besides, the ARMS2 protein has been described as a component of the extracellular matrix and its mRNA owns a unique splice form in the retina but commonly no in other tissues [15, 16].”
BackgroundKanoff, J. M., & Miller, J. W. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825292 · Cited by 15
Park, U. C., Shin, J. Y., Chung, H., & Yu, H. G. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0631-z · Cited by 14 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundGenetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
Chaudhary, V., Brent, M., Lam, W.-C., Devenyi, R., Teichman, J., Mak, M., Barbosa, J., Kaur, H., Carter, R., & Farrokhyar, F. (2016) · Ophthalmologica · doi:10.1159/000446819 · Cited by 10 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
BackgroundBardak, H., Bardak, Y., Erçalık, Y., Kumral, E. T., İmamoğlu, S., Günay, M., Özbaş, H., & Bağcı, Ö. (2016) · Genetics and Molecular Research · doi:10.4238/gmr15049164 · Cited by 7 · cited 1×
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
Background
Cited by
Disparities in Vision Health and Eye Care
Elam, A. R., Tseng, V. L., Rodriguez, T. M., Mike, E. V., Warren, A. K., Coleman, A. L., Aguwa, U., Alabiad, C., Briceno, C., Capo, H., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.07.010 · Cited by 208
Fu, Y., Zhang, Z., Webster, K. A., & Paulus, Y. M. (2024) · Biomolecules · doi:10.3390/biom14030252 · Cited by 45
Molecular Genetic Mechanisms in Age-Related Macular Degeneration
Shughoury, A., Sevgi, D. D., & Ciulla, T. A. (2022) · Genes · doi:10.3390/genes13071233 · Cited by 47
“Interestingly, while the ARMS2 rs10490924 G allele is associated with an increased risk of progression to advanced stages of disease [296], the G allele is also associated with a higher likelihood of MNV response to anti-VEGF therapy in patients who have progressed to neovascular disease [98,317,319–322], particularly…”
BackgroundGenetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113280 · Cited by 29
“ARMS2 A69S is a prognostic factor for an anti-VEGF response in wet AMD in the East Asian population, but not in the Caucasian or Middle Eastern group [48].”
BackgroundPhan, L. T., Broadhead, G., Hong, T., & Chang, A. (2021) · Clinical ophthalmology · doi:10.2147/opth.s205147 · Cited by 27
Metadata
- Authors
- Zhang, J., Liu, Z., Hu, S., & Qi, J.
- Affiliations
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Aier Eye Hospital Group (China) (CN)
- Army Medical University (CN)
- Venue
- Ophthalmic Research
- Publisher
- S. Karger AG
- Published
- 2020-05-19
- Volume
- 64
- Issue
- 2
- Pages
- 192-204
- ISSN
- 0030-3747 (ISSN-L)
- 1423-0259
- OpenAlex
- W3026686898
- Cited by
- 15
- References
- 43
- Citations by year
- 2026: 2 · 2024: 7 · 2023: 2 · 2022: 3 · 2021: 1
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- age-related macular degeneration, ARMS2, anti-VEGF therapy, treatment response, pharmacogenetics, genetic susceptibility, East Asian patients, ethnic differences
- MeSH terms
- Alleles, DNA, Genotype, Humans, Macular Degeneration, Pharmacogenetics, Proteins, Disease Management, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.